Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers

• Main Authors: Xiaojiao Li (Author), Cai Liu (Author), Xiaoxue Zhu (Author), Haijing Wei (Author), Hong Zhang (Author), Hong Chen (Author), Guiling Chen (Author), Deming Yang (Author), Hongbin Sun (Author), Zhenwei Shen (Author), Yifan Zhang (Author), Wei Li (Author), Jin Yang (Author), Yongqiang Liu (Author), Xiaojuan Lai (Author), Yanchun Gong (Author), Xuefang Liu (Author), Yongguo Li (Author), Dafang Zhong (Author), Junqi Niu (Author), Bin Liu (Author), Yanhua Ding (Author)
• Format: Book
• Published: Frontiers Media S.A., 2018-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Vicagrel is a novel anti-platelet drug and hydrolyzed to the same intermediate as clopidogrel via esterase, instead of CYP2C19. Here we report the first clinical trial on the tolerability, pharmacokinetics and pharmacodynamics of different doses of vicagrel, and comparison with clopidogr...